Total item
Cart Subtotal
$0.00 PDGFR
| Catalog No. | Inhibitor Name | PDGFR | PDGFRα | PDGFRβ | Other |
|---|---|---|---|---|---|
| A10001 | Sorafenib Tosylate | ** | ** | Raf-1,VEGFR2/Flk1,B-Raf | |
| A10468 | Imatinib Mesylate | c-Kit,v-Abl | |||
| A10880 | Sunitinib Malate | **** | FLT3,Kit,VEGFR2 | ||
| A10080 | Ponatinib | **** | Abl,VEGFR2,FGFR1 | ||
| A10103 | Axitinib | *** | **** | VEGFR1/FLT1,VEGFR2/Flk1,VEGFR3 | |
| A10259 | Imatinib | ** | c-Kit,v-Abl | ||
| A10137 | Nintedanib | ** | ** | VEGFR3,VEGFR2,LCK | |
| A10699 | Pazopanib HCl | ** | VEGFR1,VEGFR2,VEGFR3 | ||
| A11411 | Dovitinib | * | *** | FLT3,c-Kit,FGFR1 | |
| A10025 | Linifanib | ** | VEGFR1/FLT1,CSF-1R,FLT3 | ||
| A11052 | Crenolanib | **** | **** | ||
| A10558 | Masitinib | * | * | Kit,Lyn B,Abl1 | |
| A10101 | Tivozanib | *** | ** | VEGFR2,VEGFR3,EphB2 | |
| A10610 | Amuvatinib | *** | c-Kit (D816H),FLT3 (D835Y) | ||
| A10608 | Motesanib Diphosphate | ** | VEGFR1,VEGFR2,VEGFR3 | ||
| A10953 | Orantinib | *** | FGFR1,Flk1 | ||
| A11350 | CP-673451 | *** | **** | c-Kit,VEGFR2,VEGFR1 | |
| A10502 | Ki8751 | ** | VEGFR2,c-Kit,FGFR2 | ||
| A10903 | Telatinib | *** | c-Kit,VEGFR3,VEGFR2 | ||
| A11207 | PP121 | **** | Hck,VEGFR,mTOR | ||
| A11518 | Pazopanib | ** | VEGFR1,VEGFR2,VEGFR3 | ||
| A10504 | KRN 633 | * | * | VEGFR3,VEGFR2,VEGFR1 | |
| A10198 | Dovitinib Dilactic Acid | * | *** | FLT3,c-Kit,VEGFR3/FLT4 | |
| A11753 | MK-2461 | *** | c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H) | ||
| A14156 | AZD2932 | **** | Flt3,VEGFR-2,c-Kit | ||
| A15062 | DCC-2618 | *** | *** | c-Kit |
Notes:
1.Hover mouse over "" to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of "" is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.
-
Avapritinib
Catalog No. A19505 KIT and PDGFRA inhibitorAvapritinib (BLU-285) is a highly potent, selective, and orally bioavailable KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Learn More -
Pazopanib (GW-786034)
Catalog No. A11518 VEGFR inhibitorPazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. Learn More -
CP-673451
Catalog No. A11350 PDGFRα/β inhibitorCP 673451 is a potent PDGFR-β inhibitor with an IC50 of 1 nM. Learn More -
Toceranib (PHA 291639, SU 11654)
Catalog No. A11581 c-Kit, PDGFR, VEGFR inhibitorToceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Learn More -
Ki 20227
Catalog No. A11472 M-CSFR, CSF1R inhibitorKi 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R). Learn More -
Masitinib mesylate
Catalog No. A15152 KIT/PDGFR inhibitorMasitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms. Learn More -
Nintedanib esylate
Catalog No. A16197 RTK inhibitorNintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Learn More -
AC710 Mesylate
Catalog No. A16246 FLT3/KIT/PDGFRα/PDGFRβ inhibitorAC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively. Learn More -
Regorafenib Hydrochloride
Catalog No. A11546 VEGFR1/2/3/PDGFRβ/Kit/RET/Raf-1 inhibitorRegorafenib Hydrochloride is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. Learn More -
Imatinib (Gleevec)
Catalog No. A10259 PDGFR inhibitorImatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor. Learn More -
Ripretinib
Catalog No. A19508 KIT and PDGFRA switch-control inhibitorRipretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Learn More -
PDGFRα kinase inhibitor 1
Catalog No. A19632 type II PDGFRα kinase inhibitorPDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively. Learn More -
GZD856
Catalog No. A20345 PDGFRα/β inhibitorGZD856 is a novel and orally bioavailable PDGFRα/β inhibitor with IC50s of 68.6 and 136.6 nM, respectively. Learn More -
Tyrphostin AG1296
Catalog No. A16773 PDGFR inhibitorTyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Learn More -
SU4312
Catalog No. A22671 VEGFR and PDGFR tyrosine kinases inhibitorSU-4312, also known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). Learn More -
JNJ-10198409
Catalog No. A22554 PDGFRα/PDGFRβ inhbitorJNJ 10198409 is a potent platelet-derived growth factor receptor (PDGFR) inhibitor (IC50 values are 4.2 and 45 nM for PDGFRβ and PDGFRα, respectively). Also inhibits c-Abl, Lck, c-Src and Fyn kinases (IC50 values are 22, 100, 185 and 378 nM respectively). Learn More -
Seralutinib
Catalog No. A22515 PDGFR inhibitorSeralutinibm, also known as PK-10571 and GB002, is a Inhaled Pdgfr Kinase Inhibitor. Learn More -
PD-089828
Catalog No. A22103 ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFRPD089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR with IC50 of 0.15 ?M, 1.76 ?M, and 5.47 ?M, respectively. Learn More -
Bibf1120 (Nintedanib)
Catalog No. A10137 VEGFR inhibitorBIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR. Learn More -
Imatinib Mesylate
Catalog No. A10468 Bcr-Abl inhibitorImatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway. Learn More -
Ki8751
Catalog No. A10502 VEGFR-2 inhibitorKi8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays. Learn More -
Linifanib (ABT-869)
Catalog No. A10025 VEGFR/PDGFR inhibitorLinifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively. Learn More -
Crenolanib (CP-868596)
Catalog No. A11052 PDGFR/FLT3 InhibitorCrenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations. Learn More -
TSU-68 (Orantinib, SU6668)
Catalog No. A10953 PDFGRβ inhibitorOrantinib (TSU-68, SU6668) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3. Learn More -
Tivozanib (AV-951)
Catalog No. A10101 VEGFR InhibitorTivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors. Learn More -
AP24534 (Ponatinib)
Catalog No. A10080 BCR-ABL inhibitorAP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor. Learn More -
Pazopanib HCl (GW786034)
Catalog No. A10699 VEGFR/PDGFR/FGFR inhibitorPazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis. Learn More -
Sunitinib Malate
Catalog No. A10880 RTK inhibitorSunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Learn More -
Masitinib ( AB1010)
Catalog No. A10558 c-Kit inhibitorMasitinib (AB1010) is a protein tyrosine kinase inhibitor. Learn More -
Sorafenib Tosylate (Nexavar)
Catalog No. A10001 Raf inhibitorSorafenib Tosylate (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF. Learn More -
Regorafenib (BAY 73-4506)
Catalog No. A10250 VEGFR inhibitorRegorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature. Learn More -
MP470 (MP-470, Amuvatinib)
Catalog No. A10610 -
AC710
Catalog No. A15933 FLT3/KIT/PDGFRα/PDGFRβ inhibitorAC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity. Learn More -
Vorolanib
Catalog No. A19394 VEGFR/PDGFR inhibitorVorolanib (CM082; X-82) is an orally active, multikinase VEGFR/PDGFR inhibitor. Learn More -
-
New
AG1295
Catalog No. A17227 -
-
Ningetinib Tosylate
Catalog No. A17039 VEGF and PDGF inhibitorNingetinib Tosylate,also known as CT-053Tosylate and DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration. CAS: 1394820-69-9 (free base) 1394820-77-9 (tosylate) Learn More -
Flumatinib
Catalog No. A16258 multi-kinase inhibitorFlumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRbeta and c-Kit respectively. Learn More -
Telatinib (BAY 57-9352)
Catalog No. A10903 VEGFR-2 inhibitorTelatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. Learn More -
Toceranib phosphate
Catalog No. A15263 Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ. Learn More -
Regorafenib monohydrate
Catalog No. A15218 Tyrosine kinase inhibitorRegorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively. Learn More -
N-Desethyl Sunitinib
Catalog No. A15182 VEGFR/PDGFRβ/KIT inhibitorN-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively). Learn More -
PP121
Catalog No. A11207 PI3K InhibitorPP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR). Learn More -
DCC-2618
Catalog No. A15062 C-Kit/PDGFR inhibitorDCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively. Learn More -
TAK-593
Catalog No. A13555 VEGFR/PDGFR inhibitorTAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity. Learn More -
JI-101
Catalog No. A13545 VEGFR2/PDGFRβ/EphB4 inhibitorJI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities. Learn More -
AZD 2932
Catalog No. A14156 mutil-targeted protein tyrosine kinase inhibitorAZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively. Learn More -
Flumatinib mesylate
Catalog No. A13530 c-Abl/c-Kit/PDGRFβ inhibitorFlumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy. Learn More -
Motesanib Diphosphate (AMG-706)
Catalog No. A10608 VEGFR inhibitorMotesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors. Learn More -
R1530
Catalog No. A13111 Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitorR1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2. Learn More -
Dovitinib Dilactic acid (TKI258 Dilactic acid)
Catalog No. A10198 RTK inhibitorDovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively. Learn More
FILTER BY:
Shopping Options
- Actions
-
- Inhibitor (42)
- Antagonist (1)
- Target
Contact information
United StatesAdooq Bioscience
Toll Free: (866) 930-6790
Fax: +1-323-606-8156
Email: [email protected]
Not your Region? View all Distributors
Adooq Quality Guarantee
We promise all products perform as described.